Literature DB >> 34542745

Restoration of Parkinson's Disease-Like Deficits by Activating Autophagy through mTOR-Dependent and mTOR-Independent Mechanisms in Pharmacological and Transgenic Models of Parkinson's Disease in Mice.

A B Pupyshev1, M V Tenditnik2, M V Ovsyukova2, A A Akopyan2, N I Dubrovina2, M A Tikhonova2.   

Abstract

We studied the possibilities of inhibition of neurodegeneration in MPTP-induced model of Parkinson's disease (PD) in C57Bl/6J mice and transgenic model of early PD stage (5-monthold B6.Cg-Tg(Prnp-SNCA*A53T)23Mkle/J mice) by autophagy activation through mTOR-dependent and mTOR-independent pathways with rapamycin and trehalose, respectively. Therapy with autophagy inducers in a "postponed" mode (7 days after MPTP intoxication) restored the expression of the dopaminergic neuron marker tyrosine hydroxylase and markedly improved cognitive function in the conditioned passive avoidance response (CPAR; fear memory). The transgenic model also showed an increase in the expression of tyrosine hydroxylase in the nigrostriatal system of the brain. An enhanced therapeutic effect of the combined treatment with the drugs was revealed on the expression of tyrosine hydroxylase, but not in the CPAR test. Thus, activation of both pathways of autophagy regulation in PD models with weakened neuroinflammation can restore the dopaminergic function of neurons and cognitive activity in mice.
© 2021. Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  MPTP; alpha-synuclein; rapamycin; trehalose; tyrosine hydroxylase

Mesh:

Substances:

Year:  2021        PMID: 34542745     DOI: 10.1007/s10517-021-05242-z

Source DB:  PubMed          Journal:  Bull Exp Biol Med        ISSN: 0007-4888            Impact factor:   0.804


  12 in total

1.  Neuroprotective effect of the chemical chaperone, trehalose in a chronic MPTP-induced Parkinson's disease mouse model.

Authors:  Sumit Sarkar; Srinivasulu Chigurupati; James Raymick; Dushyant Mann; John F Bowyer; Tom Schmitt; Richard D Beger; Joseph P Hanig; Larry C Schmued; Merle G Paule
Journal:  Neurotoxicology       Date:  2014-07-23       Impact factor: 4.294

2.  Suppression of autophagy in the brain of transgenic mice with overexpression of А53Т-mutant α-synuclein as an early event at synucleinopathy progression.

Authors:  Alexander B Pupyshev; Tatiana A Korolenko; Anna A Akopyan; Tamara G Amstislavskaya; Maria A Tikhonova
Journal:  Neurosci Lett       Date:  2017-12-02       Impact factor: 3.046

3.  Therapeutic activation of autophagy by combined treatment with rapamycin and trehalose in a mouse MPTP-induced model of Parkinson's disease.

Authors:  Alexander B Pupyshev; Maria A Tikhonova; Anna A Akopyan; Michael V Tenditnik; Nina I Dubrovina; Tatyana A Korolenko
Journal:  Pharmacol Biochem Behav       Date:  2018-12-21       Impact factor: 3.533

4.  Regulation of autophagy by mTOR-dependent and mTOR-independent pathways: autophagy dysfunction in neurodegenerative diseases and therapeutic application of autophagy enhancers.

Authors:  Sovan Sarkar
Journal:  Biochem Soc Trans       Date:  2013-10       Impact factor: 5.407

5.  Effects of MK-801 on recognition and neurodegeneration in an MPTP-induced Parkinson's rat model.

Authors:  Ming-Hong Hsieh; Siao-Lin Gu; Shih-Chun Ho; Cornelius Rainer Pawlak; Chih-Li Lin; Ying-Jui Ho; Te-Jen Lai; Fu-Ying Wu
Journal:  Behav Brain Res       Date:  2012-01-02       Impact factor: 3.332

6.  Therapeutic effects of rapamycin on MPTP-induced Parkinsonism in mice.

Authors:  Kangyong Liu; Nan Shi; Yinyi Sun; Ting Zhang; Xiaojiang Sun
Journal:  Neurochem Res       Date:  2012-11-02       Impact factor: 3.996

7.  Trehalose, a novel mTOR-independent autophagy enhancer, accelerates the clearance of mutant huntingtin and alpha-synuclein.

Authors:  Sovan Sarkar; Janet E Davies; Zebo Huang; Alan Tunnacliffe; David C Rubinsztein
Journal:  J Biol Chem       Date:  2006-12-20       Impact factor: 5.157

Review 8.  Therapeutic potential of autophagy-enhancing agents in Parkinson's disease.

Authors:  Tim E Moors; Jeroen J M Hoozemans; Angela Ingrassia; Tommaso Beccari; Lucilla Parnetti; Marie-Christine Chartier-Harlin; Wilma D J van de Berg
Journal:  Mol Neurodegener       Date:  2017-01-25       Impact factor: 14.195

9.  A rational mechanism for combination treatment of Huntington's disease using lithium and rapamycin.

Authors:  Sovan Sarkar; Gauri Krishna; Sara Imarisio; Shinji Saiki; Cahir J O'Kane; David C Rubinsztein
Journal:  Hum Mol Genet       Date:  2007-10-06       Impact factor: 6.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.